

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in this application.

**Listing of Claims:**

1. (Canceled)
2. (Currently amended) The method according to ~~Claim 1~~ Claim 41, in which the reaction is carried out in a liquid medium containing at least 25% by weight, relative to the total weight of the liquid medium, of compound of general formula (III).
3. (Original) The method according to Claim 2, in which the liquid medium contains at least 30% by weight of compound of general formula (III).
4. (Currently amended) The method according to ~~Claim 1~~ Claim 41, in which the reaction is carried out in a liquid medium in which a concentration of the compound of general formula (II) of less than or equal to 10% by weight, relative to the total weight of the liquid medium, is maintained.
5. (Canceled)
6. (Currently amended) The method according to ~~Claim 1~~ Claim 41, in which the compound of general formula (III) is aqueous ammonia.
7. (Currently amended) The method according to ~~Claim 1~~ Claim 41, in which A is a peptide chain made up of 2 to 20 amino acids.
8. (Withdrawn) The method according to Claim 1, in which the compound of general formula (III) is a compound corresponding to general formula (I), at least R<sup>2</sup> in the compound of general formula (III) is H, A is identical in the compound of general formula (II) and in the compound of general formula (III), and the product obtained is a peptide derivative of general formula




in which A is a peptide chain comprising at least 2 enantiopure amino acids; and R<sup>1</sup> is

chosen from H, alkyl, alkenyl and aryl, which are optionally functionalized, a peptide or a nucleic acid.


9. (Canceled)
10. (Currently amended) The method according to ~~Claim 9~~ Claim 41, in which B is an amino acid.
11. (Canceled)
12. (Currently amended) The method according to ~~Claim 4~~ Claim 41, in which the group A of the compound of general formula (II) is Phe-Leu-Gly.
13. (Withdrawn) A peptide derivative of general formula
$$R^1N(CH_2-C(=O)-HN-A-COOH)_2 \quad (IV)$$
in which A denotes a peptide chain comprising at least 2 enantiopure amino acids; and  $R^1$  is chosen from H, alkyl, alkenyl and aryl, which are optionally functionalized, a peptide or a nucleic acid.
14. (Withdrawn) A peptide derivative according to Claim 13, in which the group A is chosen from Phe-Leu and Phe-Leu-Gly.
15. (Withdrawn) A peptide derivative of general formula
$$R^1N(CH_2-C(=O)-HN-A1-COOH)(CH_2-C(=O)-HN-A2-COOH) \quad (V)$$
in which A1 and A2 denote different peptide chains, and A1 or A2 comprises at least 2 enantiopure amino acids and  $R^1$  is chosen from H, alkyl, alkenyl and aryl, which are optionally functionalized, a peptide or a nucleic acid.
16. (Withdrawn) The peptide derivative according to Claim 15, wherein A1 or A2 is chosen from Phe-Leu and Phe-Leu-Gly.
17. (Withdrawn) A pharmaceutical composition comprising a the peptide derivative according to Claim 13.

18. (Withdrawn) A compound of general formula



in which X denotes a group which can be substituted by nucleophilic substitution, and Y is chosen from H and cations, and A denotes a peptide chain made up of 2 to 20 amino acids, comprising at least 2 enantiopure amino acids.

19. (Withdrawn) A method for producing the compound of general formula (II) according to Claim 18, by peptide coupling a fragment of general formula



in which X denotes a group which can be substituted by nucleophilic substitution, chosen from Cl and Br, and B denotes an amino acid or a peptide chain optionally bearing protective and/or activating groups, with a fragment F also denoting an amino acid or a peptide chain optionally bearing protective and/or activating groups.


20. (Withdrawn) The method according to Claim 18, in which B denotes an amino acid.
21. (Withdrawn) The method according to Claim 19, in which fragment F is a persilylated amino acid or a persilylated peptide chain.
22. (Withdrawn) The method according to Claim 20, in which fragment F is a persilylated amino acid or a persilylated peptide chain.
23. (Previously presented) The method according to Claim 2, in which the group A of the compound of general formula (II) is Phe-Leu-Gly.
24. (Previously presented) The method according to Claim 3, in which the group A of the compound of general formula (II) is Phe-Leu-Gly.
25. (Previously presented) The method according to Claim 4, in which the group A of the compound of general formula (II) is Phe-Leu-Gly.
26. (Canceled)

27. (Previously presented) The method according to Claim 6, in which the group A of the compound of general formula (II) is Phe-Leu-Gly.
28. (Previously presented) The method according to Claim 7, in which the group A of the compound of general formula (II) is Phe-Leu-Gly.
29. (Withdrawn) The method according to Claim 8, in which the group A of the compound of general formula (II) is Phe-Leu-Gly.
30. (Canceled)
31. (Previously presented) The method according to Claim 10, in which the group A of the compound of general formula (II) is Phe-Leu-Gly.
32. (Canceled)
33. (Withdrawn) A pharmaceutical composition comprising the peptide derivative according to Claim 14.
34. (Withdrawn) A pharmaceutical composition comprising the peptide derivative according to Claim 15.
35. (Withdrawn) A pharmaceutical composition comprising the peptide derivative according to Claim 16.
36. (Withdrawn) The compound as claimed in Claim 18, wherein the nucleophilic substitution is with Cl or Br.

Claims 37-38. (Canceled)

39. (Currently amended) The method according to ~~Claim 1~~ Claim 41, in which the reaction is carried out at a temperature of 0°C to +50°C.
40. (Currently amended) The method according to ~~Claim 1~~ Claim 41, in which the reaction is carried out at a temperature of +10°C to +40°C.

41. (New) A method for preparing a peptide of general formula



in which A is a peptide chain comprising at least two enantiopure amino acids; and  $R^1$  and  $R^2$  are each H, HN represents the terminal amino group of A and COOH represents the terminal carboxyl group of A,

comprising

- a) producing a compound of general formula



wherein

X is a group which can be substituted by nucleophilic substitution, chosen from Cl and Br;


Y is selected from the group consisting of H,  $Li^+$ ,  $Na^+$ ,  $K^+$ ,  $Cs^+$ ,  $Mg^{2+}$ ,  $Ca^{2+}$ ,  $Sr^{2+}$ , and  $Ba^{2+}$ ;

A has the same meaning as in formula (I);

HN represents the terminal amino group of A; and

COOY represents the terminal carboxyl group of A,

by peptide coupling of a fragment of general formula



wherein

X is a group which can be substituted by nucleophilic substitution, chosen from Cl and Br,

B is an amino acid or a peptide chain optionally bearing protective and/or activating groups,

HN represents the  $\alpha$ - amino group when B is an amino acid or the terminal amino group of B when B is a peptide,

with a fragment F, wherein fragment F is a persilylated amino acid or a persilylated peptide chain;

and

b) reacting said compound of general formula (II) as defined in a) with a compound of general formula  $\text{HNR}^1\text{R}^2$  (III) in which  $\text{R}^1$  and  $\text{R}^2$  are each H, wherein the reaction is carried out at a temperature of  $-30^\circ\text{C}$  to  $+60^\circ\text{C}$ .